Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm sleep disorders

A. Hida, Y. Ohsawa, S. Kitamura, K. Nakazaki, N. Ayabe, Yuki motomura, K. Matsui, M. Kobayashi, A. Usui, Y. Inoue, H. Kusanagi, Y. Kamei, K. Mishima

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

We evaluated the circadian phenotypes of patients with delayed sleep-wake phase disorder (DSWPD) and non-24-hour sleep-wake rhythm disorder (N24SWD), two different circadian rhythm sleep disorders (CRSDs) by measuring clock gene expression rhythms in fibroblast cells derived from individual patients. Bmal1-luciferase (Bmal1-luc) expression rhythms were measured in the primary fibroblast cells derived from skin biopsy samples of patients with DSWPD and N24SWD, as well as control subjects. The period length of the Bmal1-luc rhythm (in vitro period) was distributed normally and was 22.80 ± 0.47 (mean ± s.d.) h in control-derived fibroblasts. The in vitro periods in DSWPD-derived fibroblasts and N24SWD-derived fibroblasts were 22.67 ± 0.67 h and 23.18 ± 0.70 h, respectively. The N24SWD group showed a significantly longer in vitro period than did the control or DSWPD group. Furthermore, in vitro period was associated with response to chronotherapy in the N24SWD group. Longer in vitro periods were observed in the non-responders (mean ± s.d.: 23.59 ± 0.89 h) compared with the responders (mean ± s.d.: 22.97 ± 0.47 h) in the N24SWD group. Our results indicate that prolonged circadian periods contribute to the onset and poor treatment outcome of N24SWD. In vitro rhythm assays could be useful for predicting circadian phenotypes and clinical prognosis in patients with CRSDs.

元の言語英語
記事番号e1106
ジャーナルTranslational psychiatry
7
発行部数4
DOI
出版物ステータス出版済み - 1 1 2017
外部発表Yes

Fingerprint

Circadian Rhythm Sleep Disorders
Fibroblasts
Phenotype
Chronotherapy
Luciferases
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Biological Psychiatry

これを引用

Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm sleep disorders. / Hida, A.; Ohsawa, Y.; Kitamura, S.; Nakazaki, K.; Ayabe, N.; motomura, Yuki; Matsui, K.; Kobayashi, M.; Usui, A.; Inoue, Y.; Kusanagi, H.; Kamei, Y.; Mishima, K.

:: Translational psychiatry, 巻 7, 番号 4, e1106, 01.01.2017.

研究成果: ジャーナルへの寄稿記事

Hida, A, Ohsawa, Y, Kitamura, S, Nakazaki, K, Ayabe, N, motomura, Y, Matsui, K, Kobayashi, M, Usui, A, Inoue, Y, Kusanagi, H, Kamei, Y & Mishima, K 2017, 'Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm sleep disorders', Translational psychiatry, 巻. 7, 番号 4, e1106. https://doi.org/10.1038/tp.2017.75
Hida, A. ; Ohsawa, Y. ; Kitamura, S. ; Nakazaki, K. ; Ayabe, N. ; motomura, Yuki ; Matsui, K. ; Kobayashi, M. ; Usui, A. ; Inoue, Y. ; Kusanagi, H. ; Kamei, Y. ; Mishima, K. / Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm sleep disorders. :: Translational psychiatry. 2017 ; 巻 7, 番号 4.
@article{2709e90a7673408aa83bfd8eded4a51c,
title = "Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm sleep disorders",
abstract = "We evaluated the circadian phenotypes of patients with delayed sleep-wake phase disorder (DSWPD) and non-24-hour sleep-wake rhythm disorder (N24SWD), two different circadian rhythm sleep disorders (CRSDs) by measuring clock gene expression rhythms in fibroblast cells derived from individual patients. Bmal1-luciferase (Bmal1-luc) expression rhythms were measured in the primary fibroblast cells derived from skin biopsy samples of patients with DSWPD and N24SWD, as well as control subjects. The period length of the Bmal1-luc rhythm (in vitro period) was distributed normally and was 22.80 ± 0.47 (mean ± s.d.) h in control-derived fibroblasts. The in vitro periods in DSWPD-derived fibroblasts and N24SWD-derived fibroblasts were 22.67 ± 0.67 h and 23.18 ± 0.70 h, respectively. The N24SWD group showed a significantly longer in vitro period than did the control or DSWPD group. Furthermore, in vitro period was associated with response to chronotherapy in the N24SWD group. Longer in vitro periods were observed in the non-responders (mean ± s.d.: 23.59 ± 0.89 h) compared with the responders (mean ± s.d.: 22.97 ± 0.47 h) in the N24SWD group. Our results indicate that prolonged circadian periods contribute to the onset and poor treatment outcome of N24SWD. In vitro rhythm assays could be useful for predicting circadian phenotypes and clinical prognosis in patients with CRSDs.",
author = "A. Hida and Y. Ohsawa and S. Kitamura and K. Nakazaki and N. Ayabe and Yuki motomura and K. Matsui and M. Kobayashi and A. Usui and Y. Inoue and H. Kusanagi and Y. Kamei and K. Mishima",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/tp.2017.75",
language = "English",
volume = "7",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm sleep disorders

AU - Hida, A.

AU - Ohsawa, Y.

AU - Kitamura, S.

AU - Nakazaki, K.

AU - Ayabe, N.

AU - motomura, Yuki

AU - Matsui, K.

AU - Kobayashi, M.

AU - Usui, A.

AU - Inoue, Y.

AU - Kusanagi, H.

AU - Kamei, Y.

AU - Mishima, K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We evaluated the circadian phenotypes of patients with delayed sleep-wake phase disorder (DSWPD) and non-24-hour sleep-wake rhythm disorder (N24SWD), two different circadian rhythm sleep disorders (CRSDs) by measuring clock gene expression rhythms in fibroblast cells derived from individual patients. Bmal1-luciferase (Bmal1-luc) expression rhythms were measured in the primary fibroblast cells derived from skin biopsy samples of patients with DSWPD and N24SWD, as well as control subjects. The period length of the Bmal1-luc rhythm (in vitro period) was distributed normally and was 22.80 ± 0.47 (mean ± s.d.) h in control-derived fibroblasts. The in vitro periods in DSWPD-derived fibroblasts and N24SWD-derived fibroblasts were 22.67 ± 0.67 h and 23.18 ± 0.70 h, respectively. The N24SWD group showed a significantly longer in vitro period than did the control or DSWPD group. Furthermore, in vitro period was associated with response to chronotherapy in the N24SWD group. Longer in vitro periods were observed in the non-responders (mean ± s.d.: 23.59 ± 0.89 h) compared with the responders (mean ± s.d.: 22.97 ± 0.47 h) in the N24SWD group. Our results indicate that prolonged circadian periods contribute to the onset and poor treatment outcome of N24SWD. In vitro rhythm assays could be useful for predicting circadian phenotypes and clinical prognosis in patients with CRSDs.

AB - We evaluated the circadian phenotypes of patients with delayed sleep-wake phase disorder (DSWPD) and non-24-hour sleep-wake rhythm disorder (N24SWD), two different circadian rhythm sleep disorders (CRSDs) by measuring clock gene expression rhythms in fibroblast cells derived from individual patients. Bmal1-luciferase (Bmal1-luc) expression rhythms were measured in the primary fibroblast cells derived from skin biopsy samples of patients with DSWPD and N24SWD, as well as control subjects. The period length of the Bmal1-luc rhythm (in vitro period) was distributed normally and was 22.80 ± 0.47 (mean ± s.d.) h in control-derived fibroblasts. The in vitro periods in DSWPD-derived fibroblasts and N24SWD-derived fibroblasts were 22.67 ± 0.67 h and 23.18 ± 0.70 h, respectively. The N24SWD group showed a significantly longer in vitro period than did the control or DSWPD group. Furthermore, in vitro period was associated with response to chronotherapy in the N24SWD group. Longer in vitro periods were observed in the non-responders (mean ± s.d.: 23.59 ± 0.89 h) compared with the responders (mean ± s.d.: 22.97 ± 0.47 h) in the N24SWD group. Our results indicate that prolonged circadian periods contribute to the onset and poor treatment outcome of N24SWD. In vitro rhythm assays could be useful for predicting circadian phenotypes and clinical prognosis in patients with CRSDs.

UR - http://www.scopus.com/inward/record.url?scp=85038366697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038366697&partnerID=8YFLogxK

U2 - 10.1038/tp.2017.75

DO - 10.1038/tp.2017.75

M3 - Article

C2 - 28440811

AN - SCOPUS:85038366697

VL - 7

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 4

M1 - e1106

ER -